Law360, New York (September 7, 2011, 3:00 PM EDT) -- A New York federal judge on Tuesday denied a bid by a group of Chinese companies to exit multidistrict antitrust litigation over vitamin C, rejecting their claim that they were entitled to summary judgment because the Chinese government compelled them to fix prices.
In a 72-page memorandum decision and order dated Sept. 1 and docketed Tuesday, U.S. District Judge Brian Cogan nixed a summary judgment motion filed in 2009 by defendants HeBei Welcome Pharmaceutical Co. Ltd., Aland (Jiangsu) Nutraceutical Co. Ltd., Northeast Pharmaceutical Group Co. Ltd. and Shijiazhuang Pharma. Weisheng Pharmaceutical (Shijiazhuang) Co. Ltd.
The putative class action accuses the defendants...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!